Inhibition of tumor cell proliferation by SL1026 and SL1033 was demonstrated in U266B1 myeloma, HepG2 hepatoma, and U87MG glioma cells, and the potency of SOMAmer inhibition of IL-6 was equal to or greater than tocilizumab inhibition of IL-6Rα in all cases (Fig. 8). Here, IL6 is linked to plasma cell myeloma.